Aug. 24 at 2:27 PM
My top picks which I’ve recently added a lot more on the dips:
•
$RARE (Ultragenyx Pharmaceutical)
• Price: ~
$26.00 | Target:
$57.50 (+121%)
• Why: Milestone FDA approval for Genglycos (first GSDIa gene therapy) expands commercial rare-disease pipeline; strong Wall Street buy ratings.
•
$CAPR (Capricor Therapeutics)
• Price: ~
$6.30 | Target:
$21.00 (+233%)
• Why: Major late-stage catalyst setup with Deramiocel cell therapy for Duchenne muscular dystrophy moving through key regulatory steps.
•
$PATH (UiPath)
• Price: ~
$16.30 | Target:
$45.00 (+176%)
• Why: Market leader in enterprise workflow automation and agentic AI integration, presenting a steady tech-turnaround play.
•
$PROP (Prairie Operating Co.)
• Price: ~
$0.53 | Target:
$2.00 (+277%)
• Why: Speculative small-cap energy play with massive implied upside from DJ Basin asset development and turnaround momentum.
